All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The disclosure relates to the field of methods and devices for the treatment of airway tissue disorders and more particularly to the treatment of obstructive sleep apnea, and opening the airway of subjects with symptoms of obstructive sleep apnea.
The invention relates to the field of methods and devices for the treatment of airway tissue disorders and more particularly to the treatment of obstructive sleep apnea and opening the airway of subjects with symptoms of obstructive sleep apnea.
Sleep apnea is defined as the cessation of breathing for ten seconds or longer during sleep. During normal sleep, the throat muscles relax and the airway narrows. During the sleep of a subject with obstructive sleep apnea (OSA), the upper airway narrows significantly more than normal, and during an apneic event, undergoes a complete collapse that stops airflow. In response to a lack of airflow, the subject is awakened at least to a degree sufficient to reinitiate breathing. Apneic events and the associated arousals can occur up to hundreds of times per night, and become highly disruptive of sleep. Obstructive sleep apnea is commonly but not exclusively associated with a heavy body type, a consequence of which is a narrowed oropharyngeal airway.
Cyclic oxygen desaturation and fragmented sleeping patterns lead to daytime sleepiness, the hallmark symptom of the disorder. Further consequences of sleep apnea may include chronic headaches and depression, as well as diminished facilities such as vigilance, concentration, memory, executive function, and physical dexterity. Ultimately, sleep apnea is highly correlated with increased mortality and life threatening comorbidities. Cardiology complications include hypertension, congestive heart failure, coronary artery disease, cardiac arrhythmias, and atrial fibrillation. OSA is a highly prevalent disease conditions in the United States. An estimated 18 million Americans suffer from OSA to degrees that range from mild to severe, many of whom are undiagnosed, at least in part because the afflicted subjects are often unaware of their own condition.
Treatment of OSA usually begins with suggested lifestyle changes, including weight loss and attention to sleeping habits (such as sleep position and pillow position), or the use of oral appliances that can be worn at night and help position the tongue away from the back of the airway. More aggressive physical interventions include the use of breathing assist systems (such as continuous positive airway pressure machines) that provide a positive pressure to the airway through a mask worn by the subject. In some cases, pharmaceutical interventions can be helpful, but they generally are directed toward countering daytime sleepiness and do not address the root cause. Some surgical interventions are available, such as nasal surgeries, tonsillectomy and/or adenoidectomy, reductions in the soft palate or the uvula or the tongue base, or advancing the tongue base by an attachment to the mandible and pulling the base forward. These surgical approaches can be quite invasive and thus have a last-resort aspect to them and simply do not reliably alleviate or cure the condition. There is a need for less invasive procedures that show promise for greater therapeutic reliability.
Related devices and methods are described in U.S. Pat. No. 8,167,787, U.S. 2011-0144421, U.S. 2011-0226262, and U.S. patent application Ser. No. 13/308,449 to Gillis et al. filed Nov. 30, 2011 the disclosures of which are incorporated herein by reference.
The present invention provides methods and devices for treating obstructive sleep apnea, other sleep disorders, other airway problems or airway disorders, other jaw or throat problems or disorders such as snoring, other sleep-disordered breathing, other breathing difficulties, swallowing difficulties, or speech problems. Embodiments of the invention include methods for opening a collapsed or obstructed airway with devices that can be implanted into various tissues that form the airway. Embodiments of the devices include resiliently deformable materials and bioerodable materials. The deformable portion of the devices may be formed into a preferred shape and may then subsequently be deformed and stabilized in that deformed shape by incorporation or application of bioerodable materials to create a device in an implantable form. Once implanted into a tissue site, and thus exposed to an aqueous environment and to cellular and enzymatic action, the bioerodable portions of the device erode, thereby allowing the deformable portion of the device to return toward an at-rest form. Embodiments of the method, in their simplest form, thus include implanting a device, the bioerodable portion of the device bioeroding, the device changing shape as a consequence of the bioeroding, and the tissue remodeling in accordance with the force being exerted by the shape changing of the device.
One aspect of the invention provides a method of maintaining airway patency in an airway of a patient. The method includes the steps of implanting a device into airway-forming tissue without affixing the device to the tissue and permitting a bioerodable portion of the device to bioerode to apply a force to the airway-forming tissue to maintain airway patency. In some embodiments, the method also includes the step of expanding a portion of the device without affixing the device to the tissue, such as by, for example, permitting the portion of the device to self-expand. In various embodiments, the implanting step may include the step of inserting the device into the patient submandibularly, sublingually, and/or intra-orally.
In some embodiments, the permitting step includes the step of changing a shape of the device when the bioerodable portion bioerodes, such as by changing a length, curvature and/or width of the device. The method may also include the step of permitting newly formed tissue to infiltrate the device, possibly with the newly formed tissue at least partially infiltrating the device prior to applying a force to the airway-forming tissue.
In various embodiments, the implanting step includes the step of inserting the device into tongue tissue, soft palate tissue, pharyngeal wall tissue and/or epiglottis tissue. The method may also include the step of releasing a bioactive agent from the bioerodable portion as it bioerodes.
Another aspect of the invention provides a device for maintaining patency of an airway of a patient. In some embodiments, the device has a body having an at-rest shape and a deformed shape, the body being adapted to be implanted into airway-forming tissue of the patient, and proximal and distal anchors adapted to be implanted into the airway-forming tissue, without affixing the device to the tissue, and to be infiltrated by tissue to affix the anchors to the airway-forming tissue, with at least one bioerodable element maintaining the body in the deformed shape against a return force and the body being configured to return toward the at-rest shape upon erosion of the bioerodable element. In various embodiments, the body is sized and shaped to be inserted into tongue tissue, into soft palate tissue, and/or into pharyngeal tissue.
In various embodiments, the bioerodable element includes a coil and/or a C-shaped element. In some embodiments, at least one of the proximal and distal anchors is adapted to expand, possibly through self-expansion. One or more of the anchors may contain woven and/or non-woven material and may include through-holes to permit tissue in-growth. One or more of the anchors may also contain braided material.
In some embodiments, the device's deformed shape is longer, straighter and/or wider than its at-rest shape. The device may also have an elutable bioactive agent in some embodiments.
Another aspect of the invention provides an implant system for treating a sleep disorder including a bioerodable material and an elongate long term implant, the bioerodable material at least partially enveloping the elongate long term implant and resisting a compressive force of the long term implant, the bioerodable material including a first region having a first flexibility and a second region having a second flexibility that is less than the first flexibility. In some embodiments, the implant system includes a plurality of first regions having the first flexibility and a plurality of second regions having the second, lesser flexibility. In some embodiments, the second regions of lesser flexibility are configured to maintain the bioerodable material in an enveloping configuration relative to the elongate long term implant. In some embodiments, the regions of lesser flexibility are configured to substantially hold the bioerodable material in an initial shape for a period of time that is less than 16 weeks upon exposure to a body fluid (e.g. between 2 and 6 weeks or between 3 and 5 weeks).
In some embodiments, the bioerodable material includes a spring having a plurality of coils, and the first regions having the first flexibility include two coils of the spring.
In some embodiments, the second regions having the second, lesser flexibility include two points on the coils that are linked with each other.
In some embodiments, the elongate long term implant comprises a silicone material. In some embodiments, the bioerodable material includes a polymer based on lactic acid (e.g. poly(lactic acid) or poly(DL-lactic-co-glycolic acid)).
Another aspect of the invention provides an implant system for implanting in airway forming tissue including a bioerodable material and an elongate long term implant, the bioerodable material at least partially enveloping the elongate long term implant and linked between a first set of two points on the bioerodable material to form a first bridge. In some embodiments, the bioerodable material is configured to hold the elongate long term implant in an initial shape (e.g. a tensioned state).
In some embodiments the bioerodable material includes a spring having at least two coils and a plurality of points, and the first bridge connects two points on the spring. In some embodiments, the two points are on different coils at a first end of the spring. In some embodiments, the bioerodable material is linked between a second set of two points on a second set of coils of the spring to form a second bridge. In some of these embodiments the second set of coils is at a second end of the spring. In some of these embodiments, the first and second bridges are bioerodable.
In some embodiments, substantially each coil is linked to at least one other coil to form a plurality of bridges.
Yet another aspect of the invention provides a resilient elongate implant body having a first insertion shape and a second therapeutic shape, and a bioerodable material having two coils that at least partially envelop the resilient elongate implant body, and the coils are coupled together to form a coupled coil structure. In some embodiments, the bioerodable material is configured to hold the implant body in the initial insertion shape. In some of these embodiments, the bioerodable material includes additional coils continuous with the two coils to form a spring and the additional coils of the spring are wrapped around the implant body, and the two coils are at an end of the spring. In some of these embodiments, substantially each coil is coupled to at least one other coil.
Yet another aspect of the invention provides a method of manufacturing an implant system, the implant having an elongate implant body and a bioerodable support material configured to hold the elongate implant body in a first, elongate shape, the method including the steps of wrapping the bioerodable support material at least partway around the implant body, the bioerodable support material having two points on it, and coupling the two points with each other to create a coupled bioerodable support material.
Yet another aspect of the invention includes a method of manufacturing a bioerodable implant including the steps of wrapping a bioerodable material at least partway around an axis to create a wound bioerodable implant, the bioerodable material including two points, and coupling the two points to each other. In some embodiments, the wound bioerodable implant includes a helix and coupling includes heating the helix to fuse the two points.
In some embodiments, the axis includes an elongate long term implant, and the wrapping around an axis comprises wrapping the bioerodable material around the elongate long term implant to create an implant system. In some of these embodiments, the method includes applying an expansive force to the elongate long term implant with the bioerodable material to hold the long term implant in an initial shape.
In some embodiments, the coupling step includes attaching a bioerodable material to the two points to create a support strut. In some embodiments, the coupling step includes applying at least one of an adhesive, an other chemical, or an energy source to the bioerodable material. In some embodiments, the coupling step includes heating the bioerodable material to melt the two points together.
The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
With reference to
The hypopharynx 3 includes the region from the upper border of the epiglottis 12 to the inferior border of the cricoid cartilage 14. The hypopharynx 3 further includes the hyoid bone 28, a U-shaped, free-floating bone that does not articulate with any other bone. The hyoid bone 28 is attached to surrounding structures by various muscles and connective tissues. The hyoid bone 28 lies inferior to the tongue 16 and superior to the thyroid cartilage 30. A thyrohyoid membrane 17 and a thyrohyoid muscle 18 attaches to the inferior border of the hyoid 28 and the superior border of the thyroid cartilage 30. The epiglottis 12 is infero-posterior to the hyoid bone 28 and attaches to the hyoid bone by a median hyoepiglottic ligament. The hyoid bone attaches anteriorly to the infero-posterior aspect of the mandible 24 by the geniohyoid muscle.
The invention provides a method of and devices for maintaining airway patency in an airway of a patient by implanting one or more devices into airway-forming tissue and permitting a bioerodable portion of the device to bioerode, thereby applying a force to the airway-forming tissue to maintain airway patency due to, e.g., a curvature, length or width change in the device. The method may be used and/or a device may be implanted to treat a sleep disorder, snoring or any other disorder, condition or disease or to otherwise alter a shape or response of a tissue. In some embodiments, the device or devices are implanted without initially affixing the device to the tissue. Over time, tissue growth or ingrowth into the devices may provide some fixation of the devices to the airway-forming tissue prior to the bioerosion and the device shape change. Various embodiments of shape-changing implants may be used to practice the invention, and the devices may be implanted into various parts of the patient's airway-forming tissue and for various reasons, as needed.
Anchors 510 are formed at both ends of body 502. In this embodiment, anchors 510 are formed from a non-woven fabric (such as polypropylene, polyethylene, or polyester) to promote tissue ingrowth. Other anchors may be used, as desired.
Device 500 may be implanted in a patient's airway-forming tissue in the deformed shape shown in
In
Other embodiments of the airway maintaining device may use various aspects of the illustrated embodiments as needed. For example, the anchors at end of the device body may differ from each other.
In
In
The curve formed by the round data points show theoretical tensile force applied by magnet-based obstructive sleep apnea implants. As can be seen, such devices have a very narrow operational range falling with the therapeutic range providing a benefit to the patient through the application of a minimum therapeutic force.
The curves formed by the diamond and cross data points show theoretical tensile forces applied by two airway-maintaining devices according to this invention having two different spring constants in their deformable device bodies. As shown, these devices can be designed so that they provide beneficial airway maintenance therapy to the patient over a wide range of lengths.
Likewise,
In some embodiments, the device may include one or more bioactive agents in the bioerodable portion(s). Bioactive agents such as drugs or hormones that are eluted during the course of erosion of the bioerodable materials, may serve, for example, to promote healing of the implant wound, or to promote stabilization of the implanted device within the tissue site by, for example, promoting the toughening the fibrotic tissue capsule that forms around the implanted device.
It may be beneficial for a device to remain in an elongated shape until substantial or sufficient tissue growth has taken place and the ends of the device are anchored into airway tissue. However, in some conditions a device might not maintain a sufficiently elongated, (stretched) configuration as shown in
In some embodiments, an implant system according to the disclosure includes a resilient elongate implant body having a first insertion shape and a second therapeutic shape and a bioerodable material including at least two coils that at least partially envelop the resilient elongate implant body, wherein the coils are coupled together to form a coupled coil structure. A therapeutic shape of an elongate implant body may be a shape that the body takes after a bioerodable portion bioerodes. A therapeutic shape may be a shape configured to exert a desired force) on a target tissue (e.g. an airway forming tissue).
A bioerodable portion may be manufactured to better maintain an initial or desired shape, for example, by changing the way the bioerodable material is otherwise held in place relative to the resilient or elongate long term implant. The bioerodable portion may be held in position along the elongate implant in any way. For example, the portion may be held using a chemical coupling and/or using a mechanical coupling (e.g. an interlocking). To aid in device performance, including maintaining a device shape, portions of the bioerodable implant may be made less flexible compared with other, more flexible sections. The less flexible portions may hold the implant in a first shape and prevent the bioerodable portion from undergoing undesired movement (e.g. unwinding) relative to the long term implant. A point on an implant may be made less flexible, for example, by coupling one portion of a bioerodable material to another portion of the bioerodable material (e.g. coupling to itself). In one embodiment, two points on the bioerodable portion may be fused together. The two points may be on the same coils or may be on different coils.
A bioerodable portion may be manufactured to better maintain an initial or desired shape, for example, by changing the way the bioerodable material is otherwise held in place relative to the resilient or elongate long term implant. The bioerodable portion may be held in position along the elongate implant in any way. For example, the portion may be held using a chemical coupling and/or using a mechanical coupling (e.g. an interlocking). To aid in device performance, including maintaining a device shape, portions of the bioerodable implant may be made less flexible compared with other, more flexible sections. The less flexible portions may hold the implant in a first shape and prevent the bioerodable portion from undergoing undesired movement (e.g. unwinding) relative to the long term implant. A point on an implant may be made less flexible, for example, by coupling one portion of a bioerodable material to another portion of the bioerodable material (e.g. coupling to itself). In one embodiment, two points on the bioerodable portion may be fused together. The two points may be on the same coils or may be on different coils.
In some embodiments, coils may be fused at both ends of a bioerodable portion.
In another embodiment, two other coils may be fused to form a third bridge 136. The third bridge may be anywhere along the bioerodable portion, but in one particular example it is near the middle of a bioerodable portion. The third bridge may, for example, provide additional strength to the bioerodable portion to resist movement caused by mechanical agitation from airway tissue movement and may serve as a backup in the event that one of the first two bridges near an end of the bioerodable portion prematurely breaks while implanted (e.g. breaks before tissue growth has anchored the implant) such that the breakage might otherwise allow the bioerodable portion to unwind and the long term implant portion to prematurely foreshorten. A fourth, fifth, sixth, seventh, eighth or more bridges may be formed. In some embodiments, there may be a bridge at least every 1 mm, every 2 mm, every 3 mm, every 4 mm, every 5 mm, every 10 mm, or every 15 mm. In some embodiments, each coil may be fused to at least one (or at least two) other coil(s). In some embodiments, each coil may be linked to at least one other coil, forming a plurality of bridges. In one particular embodiment, all of the coils are fused together. An implant may have one, two, three or more than three separate bioerodable portions. Any (some, or all) of a bioerodable portion(s) may be fused to itself or one (or more) bioerodable portion(s) may be fused to one or more other bioerodable portion(s).
The bioerodable material may be linked or fused to itself in any way. The points on the material may be fused using a source that can generate energy (heat). The energy (heat) may melt a portion of the bioerodable material to cause it to bind to another portion of the bioerodable material and remain bound after cooling. The heat source may be a direct heat source (such as a soldering iron) that is at a temperature higher than an implant temperature or the heat source may be an indirect source such as a chemical source or light source, vibrational welding, induction welding, ultrasonic welding, or radiofrequency welding source that causes heat to be generated in the implant.
Instead, or in addition to a bioerodable material melting or otherwise linking to itself, a bioerodable material may be coupled to itself using an additional joining material such as an adhesive that bonds or a solvent that bonds by melting adjacent surfaces together or small clip or mechanical attachment to form a bridge and couple two (or more) points on the material.
Although any two (or more) coils may be connected by a bar, it may be especially useful to couple end coils, such as coils 146, 148, as shown in
A support structure between two (or more) portions of a bioerodable material may be any material that provides support (e.g. creates regions of lesser flexibility) and may be any shape (e.g. a cylinder, a sphere, a straight bar, a wavy bar, a serpentine ribbon, etc.). A bar or other joining or support material may be connected with the bioerodable material using any means (e.g. heat or mechanical). The additional joining material may be the same material as the bioerodable portion or may be a different material.
A bioerodable material that is coupled to itself may be any shape that is able to maintain a shape of the long term implant and/or resist a compressive force (or maintain a tensioned force) from the long term implant. As shown in implant system 200 in
Any method or structure that allows the bioerodable portion to maintain a long term implant in a desired shape for a desired period of time may be used. A bioerodable material may be coupled to itself using a mechanical joining to hold two (or more) portions of bioerodable material together. Any form of mechanical joining may be used (e.g. forming a crimp, mating complementary portions together).
In one embodiment, a bioerodable portion may be coupled with one or more other bioerodable portions. Two C-shaped bioerodable pieces, each of which wraps partially around an axis (e.g. a long term implant portion) may be coupled (e.g. bridged) to one another. More than two (e.g. a series) of C-shaped or other shaped bioerodable pieces may be coupled together as shown in
One aspect of the invention provides a method of manufacturing a bioerodable implant including the steps of wrapping a bioerodable material at least partway around an axis to create a wound bioerodable implant, the bioerodable implant having two points, and coupling the two points to each other. See, for example,
Another aspect of the invention provides a method of manufacturing an implant system, the implant having an elongate (or resilient) implant body and a bioerodable support material configured to hold the elongate (or resilient) implant body in a first, elongate shape, including the steps of wrapping the bioerodable support material at least partway around the implant body, the bioerodable support material having two points on it, and coupling the two points with each other to create a coupled bioerodable support material.
In one embodiment, a thin strand of a polymer may be wrapped around an axis to create a helix and the helix may be coupled to itself. In one embodiment, a polymer may be based on lactic acid and/or glycolic (e.g. poly(lactic acid) or poly(DL-lactic-co-glycolic acid)) or any of the materials listed above or known in the art. The method may further include applying an expansive force to the elongate long term implant with the bioerodable material to thereby place or hold the long term implant in an initial shape, as shown in
Another aspect of the invention provides a method of manufacturing an implant system, the implant having an elongate, resilient, long term implant body and a bioerodable (support) material configured to hold the resilient implant body in a first, elongate shape, the method including the steps of wrapping the bioerodable support material at least partway around the implant body (or at least partially enveloping the elongate implant body with a bioerodable support material), the bioerodable support material having two points on it; and coupling the two points with each other to create a coupled bioerodable support material.
In one embodiment, a ribbon like bioerodable material 172 is wrapped at least partway around axis 174, as shown in
Alternatively, or additionally to being coupled to itself, the bioerodable material may be coupled with the long term implant. The bioerodable material may be coupled with the long term implant using any method or any material(s). The coupling may serve to hold the bioerodable material in a desired shape or configuration. A bioerodable material and a long term implant may be coupled using any chemical or mechanical means, including any described elsewhere in this application. As shown in
The bioerodable material may have regions of different flexibility. The regions may hold or help hold the bioerodable material (and the long-term elongate implant) in a preferred shape.
The bioerodable material may have one or more than one (a plurality) of coils that wrap around a long axis (e.g. around a long-term elongate implant axis) no times (e.g. be a straight bar or a curve bar), or may wrap around the axis up to 1 time, up to 2 times, up to 3 times, up to 4 times, up to 5 times, up to 10 times, up to 20 times, up to 30 times, up to 40 times, or more than 40 times.
The long term implant portion may have none, one or more than one wide portions that separate narrow portions. The wide portion may have a tensioned configuration and may provide a compressive force to the bioerodable portion such that the bioerodable portion holds the long-term implant portion in a preferred shape.
The long-term implant portion may couple with the bioerodable portion in any way (e.g. chemically, mechanically).
If different and multiple regions of coils are fused, a range of contraction times of the long term implant portion could be generated. Note that coil diameter also contributes to rate of contraction but may be secondary to coil fusion. In in vitro tests, the durometer of the material influenced contraction in the least significant manner. Nonetheless, taken together these parameters could be used to generate a matrix of physical properties that could influence the timing of the degradation of the coils, as well as match the bending properties of the device as a whole to tongue or other airway implant motion.
Any of the features described herein may be combined with any other features herein or as is known in the art. For example, any implant or any system may have a region(s) configured to be externally identifiable or visible or made externally identifiable or visible (e.g. by fluoroscopy), such as to a health care provider (physician) to aid in device placement, device tracking, and/or device removal. A region, such as wide sections 108 shown in
The devices may alternatively, or additionally, have reinforced anchor portions. The reinforced anchor portions may allow tissue to grow on or through an anchor portion and may serve to better anchor a device in place. The reinforced anchor portions may help hold an implant in place and/or may keep an implant from undergoing undesired stretching.
Referring to
The devices described herein may be combined with other device features, including, but not limited to those described in U.S. Pat. No. 8,167,787, U.S. 2011/0144421, U.S. 2011/0226262, and U.S. patent application Ser. No. 13/308,449 to Gillis et al. filed Nov. 30, 2011.
Any of the devices or systems described herein may be configured to substantially hold the bioerodable material and/or may be configured to hold the long term implant in an initial (e.g. a first or a non-final) shape or configuration for less than 16 weeks (e.g. between 2 and 6 weeks, between 3 and 5 weeks, or for less than 1 week, less than 2 weeks, less than 3 weeks, less than 4 weeks, less than 5 weeks, less than 6 weeks, less than 7 weeks, or less than 8 weeks) when exposed to a body fluid or a saline solution. A body fluid that the device may be exposed to may be, for example, blood, interstitial fluid, lymph, mucus, nasal exudate or discharge, and/or saliva. A saline solution may be any saline solution, including a buffered saline solution. In one particular example, it is 0.1 M saline (0.1 M sodium chloride). After exposure to a body fluid for a sufficient period of time, an implant may take on a second, final, or therapeutic shape or configuration.
An in vitro test system was developed to demonstrate the fatigue behavior of the restricting coils and simulate the expected motion after implantation. While not wishing to be limited to any theory, it is thought that the characteristic motions of the coiled implant when implanted are initially multiplanar bending. While some stretching of the device may occur, contraction is substantially prevented until the supporting coils degrade.
In order to evaluate the relative performance of types of coils, sets of implants with different durometer silicone cores and with coils that were either fused or open-ended within segments were rested. Coils with diameters of 0.009″ or 0.013″ were tested in 0.1 M saline at 37° C. in a 20 L bath. The coils were made to oscillate by fixing one end and placing the body of the implant in a moving stream such that bending occurred at an approximate frequency of 2 Hz with a randomly oriented 15 degree to 30 degree bending motion. Bacterial growth was inhibited by addition of 0.01% sodium azide. Solutions were replaced each week and refreshed daily to replace fluid lost by evaporation. Temperature was maintained with the use of a submersible thermocouple regulated coil heater.
In general, regardless of the durometer of the silicone core tested, coil segments that were not fused at both ends began to unravel at their distal ends, causing a decrease in the stretched length of the implant from 36+/−1 mm to 21 to 27 mm by day 10 of the test. In contrast, implant systems with coils that were fused relaxed a stretched length of about 36 mm to about 34 mm by day 10.
Silicone cores with unfused coils contracted to 18 mm, which is their relaxed state, by day 15. For the fused coil materials tested, the rate of contraction depended little upon the durometer of the material or the diameter of the coil. The higher durometer (50 D) material tested with 0.013″ diameter fused coils contracted the least, contracting to only about 34 mm. 40 D material tested under the same conditions contracted to about 32 mm. This difference is small compared to the contraction levels observed in unfused coils and shows that although use of a higher durometer material can greatly increase the force on the coils, its effect is far less significant than is coil fusion. This suggests that the greatest impact on maintaining stretched implant length and avoiding early (premature) contraction was created by fusing coils.
The effect of fusing implant coils together to prevent the coils from prematurely unwinding on the implant contraction rate was further tested using a canine animal model. Comparable implant systems having resilient, long term implants initially held in expanded shapes by coiled bioerodable implant material with (
As for additional details pertinent to the present invention, materials and manufacturing techniques may be employed as within the level of those with skill in the relevant art. The same may hold true with respect to method-based aspects of the invention in terms of additional acts commonly or logically employed. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Likewise, reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “and,” “said,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The breadth of the present invention is not to be limited by the subject specification, but rather only by the plain meaning of the claim terms employed.
Number | Name | Date | Kind |
---|---|---|---|
4424208 | Wallace et al. | Jan 1984 | A |
4582640 | Smestad et al. | Apr 1986 | A |
4978323 | Freedman | Dec 1990 | A |
5041138 | Vacanti et al. | Aug 1991 | A |
5145935 | Hayashi | Sep 1992 | A |
5326355 | Landi | Jul 1994 | A |
5372600 | Beyar et al. | Dec 1994 | A |
5428024 | Chu et al. | Jun 1995 | A |
5506300 | Ward et al. | Apr 1996 | A |
5531761 | Yoon | Jul 1996 | A |
5665822 | Bitler et al. | Sep 1997 | A |
5697779 | Sachdeva et al. | Dec 1997 | A |
5762599 | Sohn | Jun 1998 | A |
5775322 | Silverstein et al. | Jul 1998 | A |
5782636 | Armstrong et al. | Jul 1998 | A |
5972000 | Beyar et al. | Oct 1999 | A |
5972111 | Anderson | Oct 1999 | A |
5979456 | Magovern | Nov 1999 | A |
5988171 | Sohn et al. | Nov 1999 | A |
6019779 | Thorud et al. | Feb 2000 | A |
6161541 | Woodson | Dec 2000 | A |
6165486 | Marra et al. | Dec 2000 | A |
6197043 | Davidson | Mar 2001 | B1 |
6231605 | Ku | May 2001 | B1 |
6250307 | Conrad et al. | Jun 2001 | B1 |
6388043 | Langer et al. | May 2002 | B1 |
6390096 | Conrad et al. | May 2002 | B1 |
6395017 | Dwyer et al. | May 2002 | B1 |
6401717 | Conrad et al. | Jun 2002 | B1 |
6415796 | Conrad et al. | Jul 2002 | B1 |
6431174 | Knudson et al. | Aug 2002 | B1 |
6439238 | Brenzel et al. | Aug 2002 | B1 |
6450169 | Conrad et al. | Sep 2002 | B1 |
6453905 | Conrad et al. | Sep 2002 | B1 |
6458127 | Truckai et al. | Oct 2002 | B1 |
6467485 | Schmidt | Oct 2002 | B1 |
6502574 | Stevens et al. | Jan 2003 | B2 |
6507675 | Lee et al. | Jan 2003 | B1 |
6513530 | Knudson et al. | Feb 2003 | B2 |
6513531 | Knudson et al. | Feb 2003 | B2 |
6516806 | Knudson et al. | Feb 2003 | B2 |
6523541 | Knudson et al. | Feb 2003 | B2 |
6523542 | Knudson et al. | Feb 2003 | B2 |
6530896 | Elliott | Mar 2003 | B1 |
6546936 | Knudson et al. | Apr 2003 | B2 |
6569191 | Hogan | May 2003 | B1 |
6578763 | Brown | Jun 2003 | B1 |
6601584 | Knudson et al. | Aug 2003 | B2 |
6626181 | Knudson et al. | Sep 2003 | B2 |
6626916 | Yeung et al. | Sep 2003 | B1 |
6629988 | Weadock | Oct 2003 | B2 |
6634362 | Conrad et al. | Oct 2003 | B2 |
6636767 | Knudson et al. | Oct 2003 | B1 |
6703040 | Katsarava et al. | Mar 2004 | B2 |
6748950 | Clark et al. | Jun 2004 | B2 |
6748951 | Schmidt | Jun 2004 | B1 |
6772944 | Brown | Aug 2004 | B2 |
6899105 | Krueger et al. | May 2005 | B2 |
7017582 | Metzger et al. | Mar 2006 | B2 |
7063089 | Knudson et al. | Jun 2006 | B2 |
7090672 | Underwood et al. | Aug 2006 | B2 |
7107992 | Brooks et al. | Sep 2006 | B2 |
D536792 | Krueger et al. | Feb 2007 | S |
7192443 | Solem et al. | Mar 2007 | B2 |
7213599 | Conrad et al. | May 2007 | B2 |
7255110 | Knudson et al. | Aug 2007 | B2 |
7322356 | Critzer et al. | Jan 2008 | B2 |
7337781 | Vassallo | Mar 2008 | B2 |
7793661 | Macken | Sep 2010 | B2 |
7824704 | Anderson et al. | Nov 2010 | B2 |
7909037 | Hegde et al. | Mar 2011 | B2 |
7909038 | Hegde et al. | Mar 2011 | B2 |
7934506 | Woodson et al. | May 2011 | B2 |
7947076 | Vassallo et al. | May 2011 | B2 |
7992567 | Hirotsuka et al. | Aug 2011 | B2 |
7997266 | Frazier et al. | Aug 2011 | B2 |
8167787 | Gillis | May 2012 | B2 |
8186355 | van der Burg et al. | May 2012 | B2 |
8220466 | Frazier et al. | Jul 2012 | B2 |
8409296 | Knize et al. | Apr 2013 | B2 |
8528564 | Paraschac et al. | Sep 2013 | B2 |
9050176 | Datta et al. | Jun 2015 | B2 |
9161855 | Rousseau et al. | Oct 2015 | B2 |
20010051815 | Esplin | Dec 2001 | A1 |
20020020417 | Nikolchev et al. | Feb 2002 | A1 |
20020116050 | Kocur | Aug 2002 | A1 |
20020116070 | Amara et al. | Aug 2002 | A1 |
20030149445 | Knudson et al. | Aug 2003 | A1 |
20040045556 | Nelson et al. | Mar 2004 | A1 |
20040139975 | Nelson et al. | Jul 2004 | A1 |
20040204734 | Wagner et al. | Oct 2004 | A1 |
20050004417 | Nelson et al. | Jan 2005 | A1 |
20050065615 | Krueger et al. | Mar 2005 | A1 |
20050090861 | Porter | Apr 2005 | A1 |
20050092332 | Conrad et al. | May 2005 | A1 |
20050115572 | Brooks et al. | Jun 2005 | A1 |
20050121039 | Brooks et al. | Jun 2005 | A1 |
20050154412 | Krueger et al. | Jul 2005 | A1 |
20050171572 | Martinez | Aug 2005 | A1 |
20050199248 | Pflueger et al. | Sep 2005 | A1 |
20050267321 | Shadduck | Dec 2005 | A1 |
20050274384 | Tran et al. | Dec 2005 | A1 |
20060150986 | Roue et al. | Jul 2006 | A1 |
20060201519 | Frazier et al. | Sep 2006 | A1 |
20060207606 | Roue et al. | Sep 2006 | A1 |
20060229669 | Mirizzi et al. | Oct 2006 | A1 |
20060235380 | Vassallo | Oct 2006 | A1 |
20060260623 | Brooks et al. | Nov 2006 | A1 |
20060289014 | Purdy et al. | Dec 2006 | A1 |
20060289015 | Boucher et al. | Dec 2006 | A1 |
20070010787 | Hackett et al. | Jan 2007 | A1 |
20070108077 | Lung et al. | May 2007 | A1 |
20070144534 | Mery et al. | Jun 2007 | A1 |
20070198040 | Buevich et al. | Aug 2007 | A1 |
20070261701 | Sanders | Nov 2007 | A1 |
20070288057 | Kuhnel | Dec 2007 | A1 |
20070295340 | Buscemi | Dec 2007 | A1 |
20080023012 | Dineen et al. | Jan 2008 | A1 |
20080027560 | Jackson et al. | Jan 2008 | A1 |
20080053461 | Hirotsuka et al. | Mar 2008 | A1 |
20080058584 | Hirotsuka et al. | Mar 2008 | A1 |
20080066764 | Paraschac et al. | Mar 2008 | A1 |
20080066765 | Paraschac et al. | Mar 2008 | A1 |
20080066766 | Paraschac et al. | Mar 2008 | A1 |
20080066767 | Paraschac et al. | Mar 2008 | A1 |
20080066769 | Dineen et al. | Mar 2008 | A1 |
20080078411 | Buscemi et al. | Apr 2008 | A1 |
20080078412 | Buscemi et al. | Apr 2008 | A1 |
20080082113 | Bishop et al. | Apr 2008 | A1 |
20080188947 | Sanders | Aug 2008 | A1 |
20090038623 | Farbarik et al. | Feb 2009 | A1 |
20090044814 | Iancea et al. | Feb 2009 | A1 |
20090084388 | Bagley et al. | Apr 2009 | A1 |
20090126742 | Summer | May 2009 | A1 |
20090319046 | Krespi et al. | Dec 2009 | A1 |
20100037901 | Rousseau et al. | Feb 2010 | A1 |
20100132719 | Jacobs et al. | Jun 2010 | A1 |
20100158854 | Puisais | Jun 2010 | A1 |
20100163056 | Tschopp et al. | Jul 2010 | A1 |
20110100377 | Weadock et al. | May 2011 | A1 |
20110144421 | Gillis | Jun 2011 | A1 |
20110166598 | Gonazles et al. | Jul 2011 | A1 |
20110174315 | Zhang et al. | Jul 2011 | A1 |
20110226262 | Gillis et al. | Sep 2011 | A1 |
20110226263 | Gillis et al. | Sep 2011 | A1 |
20110290258 | Pflueger et al. | Dec 2011 | A1 |
20110308529 | Gillis et al. | Dec 2011 | A1 |
20110308530 | Gillis et al. | Dec 2011 | A1 |
20120017919 | Gillis | Jan 2012 | A1 |
20120024298 | Gillis et al. | Feb 2012 | A1 |
20120132214 | Gillis | May 2012 | A1 |
20120138069 | Gillis et al. | Jun 2012 | A1 |
20120143134 | Hollis et al. | Jun 2012 | A1 |
20120180799 | Pflueger et al. | Jul 2012 | A1 |
20120197070 | Gillis | Aug 2012 | A1 |
20130056009 | Mohan et al. | Mar 2013 | A1 |
20130098374 | Gillis et al. | Apr 2013 | A1 |
20130109910 | Alexander et al. | May 2013 | A1 |
20130233324 | Witt et al. | Sep 2013 | A1 |
20130312767 | Gillis | Nov 2013 | A1 |
20130319427 | Sung et al. | Dec 2013 | A1 |
20140246027 | Gillis et al. | Sep 2014 | A1 |
20150032028 | Rampersaud et al. | Jan 2015 | A1 |
20150202074 | Gillis et al. | Jul 2015 | A1 |
Number | Date | Country |
---|---|---|
1216013 | Jun 2006 | EP |
2561842 | Feb 2013 | EP |
05-337126 | Dec 1993 | JP |
2604833 | Jan 1997 | JP |
2001198147 | Jul 2001 | JP |
2006507038 | Mar 2006 | JP |
2007-97706 | Apr 2007 | JP |
2007-512090 | May 2007 | JP |
2007229485 | Sep 2007 | JP |
2007525277 | Sep 2007 | JP |
WO 9718854 | May 1997 | WO |
WO 9900058 | Jan 1999 | WO |
WO 0066050 | Nov 2000 | WO |
WO 0189426 | Nov 2001 | WO |
WO 0213738 | Feb 2002 | WO |
WO 02076341 | Oct 2002 | WO |
WO 02076352 | Oct 2002 | WO |
WO 02076353 | Oct 2002 | WO |
WO 02076354 | Oct 2002 | WO |
WO 03041612 | May 2003 | WO |
WO 03055417 | Jul 2003 | WO |
WO 03065947 | Aug 2003 | WO |
WO 2005044158 | May 2005 | WO |
WO 2006012188 | Feb 2006 | WO |
WO 2006093533 | Sep 2006 | WO |
WO 2006101610 | Sep 2006 | WO |
WO 2007056583 | May 2007 | WO |
WO 2007070024 | Jun 2007 | WO |
WO 2008042058 | Apr 2008 | WO |
WO 2008097890 | Aug 2008 | WO |
WO 2009032625 | Mar 2009 | WO |
WO 2010028036 | Mar 2010 | WO |
WO 2010045546 | Apr 2010 | WO |
WO 2010051195 | May 2010 | WO |
WO 2013182893 | Dec 2013 | WO |
Entry |
---|
Jeon et al.; Shape memory and nonostructure in poly(norbornyl-POSS) copolymers; Polym Int; vol. 49(5); pp. 453-457; May 2000. |
Lui et al.; Thermomechanical characterization of a tailored series of shape memory polymers; J Applied Med Polymers; vol. 6/ No. 2; pp. 47-52; Sep. 2002. |
Mather et al.; Strain recovery in POSS hybrid thermoplastics; Polymer Preprints; vol. 41, No. 1; pp. 528-529; 2000 (month unavailable). |
Gillis; U.S. Appl. No. 14/282,943 entitled “Partially erodable systems for treatment of obstructive sleep apnea,” filed May 20, 2014. |
Gillis et al.; U.S. Appl. No. 14/289,475 entitled “Systems and methods for treatment of sleep apnea,” filed May 28, 2014. |
DeRowe et al.; A minimally invasive technique for tongue base stabilation in obstructive sleep apnea; Operative Techniques in Otolaryngology-Head and Neck Surgery; 11(1); pp. 41-46; Mar. 2000. |
Miller et al.; Role of the tongue base supension suture with the Repose System bone screw in multileval surgical management of obstructive sleep apnea; Otolaryngol Head Neck Surg.; 126(4); pp. 392-398; Apr. 2002. |
Walker et al.; Palatal implants for snoring and sleep apnea; Operative Techniques in otolaryngology; 17(4); pp. 238-241; Dec. 2006. |
Woodson et al.; Pharyngeal suspension suture with Repose bone screw for obstructive sleep apnea; Otolaryngol Head Neck Surg.; 122(3); pp. 395-401; Mar. 2000. |
Gillis et al.; U.S. Appl. No. 13/935,052 entitled “Systems and Methods for Treatment of Sleep Apnea,” filed Jul. 3, 2013. |
Gillis et al.; U.S. Appl. No. 13/939,107 entitled “Systems and Methods for Treatment of Sleep Apnea,” filed Jul. 10, 2013. |
Collins English Dictionary; “elastomer” (definition); Complete & Unabridged; 10th Edition; HarperCollins Publishers; May 11, 2015; retrieved from the Internet (http://dictionary.reference.com/browse/elastomeric>). |
Gillis et al.; U.S. Appl. No. 14/877,862 entitled “Systems and methods for treatment of sleep apnea,” filed Oct. 7, 2015. |
Number | Date | Country | |
---|---|---|---|
20140000631 A1 | Jan 2014 | US |